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Nursing strategies for thinking critically and acting decisively
Amy Goodrich, MSN, CRNP, Nina Wagner-Johnston, MD, and Dana Delibovi, MA, MS
THERAPY FOR LYMPHOMAS HAS CHANGED MARKEDLY in recent years (National 
Comprehensive Cancer Network [NCCN], 2016c, 2016d). Treatment of 
B-cell lymphomas has been enhanced by rituximab (Rituxan®) immunother-
apy; novel targeted therapies, such as bortezomib (Velcade®), lenalidomide 
(Revlimid®), and idelalisib (Zydelig®); bendamustine (Treanda®) chemother-
apy; and other innovations (Coiffier et al., 2002; Fowler et al., 2011, 2014; 
NCCN, 2016d; Rummel et al., 2013). Patients with T-cell lymphomas may now 
receive histone deacetylase inhibitors and other targeted agents (Duvic et al., 
2009). For patients with Hodgkin lymphoma (HL), although chemotherapy 
remains the standard of care, targeted therapies and immunotherapies may 
also be indicated as second-line treatment (Ansell et al., 2013; Johnston et al., 
2010; Moskowitz et al., 2015).
A growing number of treatment options, combined with the heterogeneity 
of HL and non-Hodgkin lymphoma (NHL), have created nursing challenges in 
the management of adverse events (AEs). Nurses are the most trusted health-
care team members (Newport, 2012). This puts the oncology nurse in a strong 
position to assess toxicities with the highest level of patient input, to gather in-
formation about overall distress related to the toxicities, and to learn how the 
toxicities are impacting the patient’s routine activities and daily quality of life. 
Nurses are called on to identify a host of AEs in a wide variety of regimens, and 
differentiate these AEs from complex lymphoma symptom patterns. Nurses 
must then grade each AE accurately, and determine which of the multiple anti- 
lymphoma drugs in the regimen may have caused the AE. Finally, nurses must 
collaborate with the interdisciplinary care team to recommend whether to ad-
just therapy based on the grade and description of the AE, distress level, and 
impact on quality of life. The recommendation from nurses is essential to help 
the patient and clinical team come to a shared decision on therapy adjustment. 
These activities require nurses to think critically and act decisively by 
conducting a logical and systematic analysis to determine AE grade, deciding 
on a recommendation for intervention, and communicating persuasively to 
the interdisciplinary team, the patient, and the caregiver (Brenner, Hughes, & 
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BACKGROUND: Multiple treatment options, com-
bined with disease heterogeneity, have created 
nursing challenges in the management of adverse 
events (AEs) during antilymphoma therapy. Testing 
has revealed that less than half of participating 
nurses correctly graded peripheral neuropathy and 
neutropenia related to antilymphoma regimens.
OBJECTIVES: This article identifies nursing challeng-
es in the management of AEs associated with ther-
apy for lymphomas and describes how strategies in 
critical thinking can help meet those challenges.
METHODS: A comprehensive literature search in 
oncology nursing, nursing education, and critical 
thinking was conducted; participant responses to 
pre- and post-tests at nursing education programs 
were evaluated; and a roundtable meeting of 
authors was convened.
FINDINGS: Oncology nurses can cultivate critical 
thinking skills, practice thinking critically in 
relation to team members and patients, leverage 
information from the Patient-Reported Outcomes 
Common Terminology Criteria for Adverse Events, 
and manage workflow to allow more opportunity 
for critical thinking.
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Sutphen, 2008). This skill set is not limited to lymphoma; it applies 
across all types of malignancies. Lymphoma treatment, because 
it encompasses so many regimens and virtually all types of AEs, 
provides an optimal model for AE management across cancer 
care. The problems and solutions presented in this article are ap-
plicable to lymphomas but certainly extend beyond lymphoma to 
other cancers (see Appendix A). 
Nurses can access a number of valuable resources to enhance 
their knowledge and competency regarding the assessment and 
management of AEs. Among these are guidelines from the NCCN 
(2016a, 2016b) on supportive care and the Oncology Nursing 
Society’s ([ONS’s], 2016) Putting Evidence Into Practice resourc-
es. An overview of all lymphoma treatment toxicities is beyond the 
scope of this article but can be found in McFadden, Poniatowski, 
and Temple’s (2006) Contemporary Issues in Lymphoma: A Nursing 
Perspective and, for more recently introduced regimens, in NCCN 
(2016c, 2016d) guidelines for NHL and HL.
Challenges 
Lymphoma treatment options are so vast that virtually every pos-
sible AE may occur. For example, hematologic toxicities that in-
clude anemia, neutropenia, and thrombocytopenia are common 
to cytotoxic drugs and molecularly targeted agents. IV doxorubi-
cin (Adriamycin®), cyclophosphamide (Cytoxan®), oral lenalido-
mide, and numerous other drugs may produce grade 3–4 neutro-
penia (Baxter Healthcare, 2010; Celgene Corporation, 2015; Pfizer 
Laboratories, 2015) Peripheral neuropathy may occur with drugs 
as diverse as bortezomib (Velcade®), vincristine (Oncovin®), car-
boplatin (Paraplatin®), brentuximab vedotin (Adcetris®), alemtu-
zumab (Lemtrada®), and many more (Genzyme Corporation, 
2014; Grisold, Cavaletti, & Windebank, 2012; Millennium 
Pharmaceuticals, Inc., 2015; Seattle Genetics, 2015). Serious mu-
cocutaneous reactions are associated with a range of drugs—
from the antibody rituximab to cytotoxic therapy like bendamus-
tine (Genentech, 2014; Teva Pharmaceuticals, 2015). Fatigue and 
gastrointestinal (GI) effects are ubiquitous reactions to antican-
cer therapy (NCCN, 2016a, 2016b), and some injectable drugs, 
notably antibodies, carry high risk for hypersensitivity infusion 
reactions (Genentech, 2014; Genzyme Corporation, 2014). Older 
chemotherapy drugs, which are still heavily relied upon in current 
regimens, are characterized by potentially severe and dose-limiting 
GI, mucosal, and hematologic AEs. 
Because antilymphoma therapy often relies on drug com-
binations (see Figures 1 and 2), additive or synergistic toxicity 
of drugs in the regimen may occur. The introduction of novel 
agents into combinations may produce new interactions or tox-
icities that will not be fully understood without more clinical 
experience. The potential exacerbation of toxicities in combi-
nation therapy complicates the already intricate set of AEs in 
antilymphoma therapy. In addition, various lymphomas have 
disease-related symptom patterns that mimic treatment-related 
symptoms. For example, pruritus and fatigue may occur in HL 
and B-cell NHLs, and anemia in diffuse large B-cell lymphoma 
(NCCN, 2016c, 2016d).
In this complex setting, inaccurate grading of AEs, uncertainty 
or errors in decisions to adjust therapy, and ineffective team com-
munication represent significant hurdles to effective care (Cirillo 
et al., 2009; Schulmeister, 2006). Unfavorable outcomes can re-
sult, including risks to patient safety (e.g., toxicities graded inac-
curately low) and less-optimal treatment efficacy (e.g., drugs are 
withheld because of inaccurate high grades on AEs or miscommu-
nication of grade). These hurdles contribute to conditions that 





 ɔ ABVE-PC—doxorubicin hydrochloride, bleomycin sulfate, vincristine 
sulfate, etoposide, prednisone, cyclophosphamide
 ɔ BEACOPP—bleomycin sulfate, etoposide phosphate, doxorubicin hydro-
chloride plus COPP
 ɔ COPP—cyclophosphamide, vincristine, procarbazine, prednisone
 ɔ COPP-ABV—COPP plus doxorubicin hydrochloride, bleomycin sulfate, 
vinblastine sulfate
 ɔ ICE—ifosfamide, carboplatin, etoposide
 ɔ MOPP—mechlorethamine hydrochloride, vincristine sulfate, procarbazine 
hydrochloride, prednisone
 ɔ OEPA—vincristine sulfate, etoposide, prednisone, doxorubicin hydrochloride
 ɔ OPPA—vincristine sulfate, prednisone, procarbazine hydrochloride, 
doxorubicin hydrochloride
 ɔ Stanford V—mechlorethamine, doxorubicin hydrochloride, vinblastine 
sulfate, vincristine sulfate, bleomycin sulfate, etoposide phosphate, 
prednisone
 ɔ VAMP—vincristine sulfate, doxorubicin hydrochloride, methotrexate, 
prednisone
Note. Combinations may contain additional chemotherapy drugs in long use for 
many types of cancer. 
Note. Based on information from National Comprehensive Cancer Network, 2016c. 
 ɔ Bleomycin










 ɔ Procarbazine hydrochloride
 ɔ Rituximab
 ɔ Romidepsin
 ɔ Vinblastine sulfate












































































































4 CLINICAL JOURNAL OF ONCOLOGY NURSING VOLUME 21, NUMBER 1 CJON.ONS.ORG
LYMPHOMA THERAPY AND ADVERSE EVENTS
Grading
During lymphoma treatment, nurses confront the documented 
challenge of AE grading during assessment and care (Cirillo et al., 
2009; Schulmeister, 2006; Trotti, Colevas, Setser, & Basch, 2007). 
Grading inaccuracy can lead to clinical deficits, including under-
estimation of toxicity and the potential for avoidable risk, as well 
as overestimation of toxicity, leading to unnecessary dose reduc-
tion or therapy termination. Grading of many AEs include impact 
on quality of life, so that the nurse, by making this quality-of-life 
assessment, is among the most strongly positioned healthcare 
team member to evaluate and report this critical consideration.
Participant responses during 10 nursing education programs, 
conducted at ONS Chapters, revealed gaps in grading knowledge 
among nurses (Rogers, 2015). An author of the current article 
(AG) served as a faculty member for these programs. Program 
participants were presented with six cases and were informed that 
the cases pertained to peripheral neuropathy, neutropenia, or in-
fusion reactions. They were asked to identify the symptom or AE, 
grade it, and, if appropriate, provide treatment options for that 
toxicity and grade. Participant responses were analyzed by an ad-
visor to this article, Barbara Rogers, CRNP, MN, AOCN®, ANP-BC. 
Responses revealed that only a minority of participating nurses 
could correctly grade the severity of two common AEs in lympho-
ma therapy—peripheral neuropathy and neutropenia. In another 
activity, a higher proportion of participants could correctly grade 
infusion reactions, but their ability to grade accurately was far 
from universal for this potentially serious AE (see Table 1). 
In a blinded survey (Cirillo et al., 2009), nurses graded AEs 
more accurately than physicians via the well-established crite-
ria of the Common Terminology Criteria for Adverse Events 
(CTCAE) (see Table 2). In the study, accuracy was measured 
by the key parameter of patient–clinician agreement (Cirillo 
et al., 2009; National Cancer Institute [NCI], 2010; Pakhomov, 
Jacobsen, Chute, & Roger, 2008). However, better accuracy did 
not always mean higher nurse accuracy. Nurse–patient agreement 
in the grading of sensory neuropathy, mucositis, and asthenia was 
65% or less by kappa coefficient (KC) (defined as the percentage 
by which agreement exceeds that expected by chance). Nurse– 
patient agreement was higher for GI AEs (range = 74%KC to 85%KC) 
(Cirillo et al., 2009). 
Although nurses may exhibit a skill gap in grading AEs, they 
display much less of a gap in the identification of AEs. In pre- 
and post-testing during the ONS Chapters education programs, 
more than 91% of nurses correctly identified peripheral neurop-
athy, neutropenia, and infusion reaction related to lymphoma 
treatment. In addition, survey data show patient–nurse agreement 
of 75%KC or greater for identification of six treatment-emergent 
AEs—asthenia, nausea, mucositis, sensory neuropathy, constipa-
tion, and diarrhea—all of which may occur during one or more 
forms of lymphoma therapy (Cirillo et al., 2009).
Barriers to Grading
Undeniably, grading of AEs is difficult. A nurse engaged in grading 
is engaged in an analytic process that demands high-level critical 
thinking. Several aspects, however, conspire to impair the nurse’s 
ability to think critically during grading. The first arises from the 
CTCAE itself, which has the potential for incomplete report-
ing (Trotti et al., 2007). CTCAE is clinician-centric rather than 
patient-centric; it does not capture patient self-report of AEs, 
severity, or impact. Instead, the CTCAE captures the clinician’s 
analysis of laboratory-based events (e.g., blood counts), events 
observable on examination (e.g., tremor), and symptomat-
ic events (e.g., nausea) (Basch et al., 2014; Trotti et al., 2007). 
However, accruing evidence has shown that patient self-reports of 
toxicity are a better gauge of health status than clinician reports, 





 ɔ ABVD—doxorubicin, bleomycin, vinblastine, dacarbazine
 ɔ ABVE—doxorubicin, bleomycin, vincristine, etoposide
 ɔ BR—bendamustine, rituximab
 ɔ CHOP—cyclophosphamide, doxorubicin, vincristine, prednisone
 ɔ COPP—cyclophosphamide, vincristine, procarbazine, prednisone
 ɔ CVP—cyclophosphamide, vincristine, prednisone
 ɔ EPOCH—etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin
 ɔ ESHAP—etoposide, methylprednisolone, cytarabine, cisplatin
 ɔ Hyper-CVAD—cyclophosphamide, vincristine, doxorubicin, dexamethasone
 ɔ ICE—ifosfamide, carboplatin, etoposide
 ɔ R-CHOP—rituximab plus CHOP
 ɔ R-CVP—rituximab plus CVP
 ɔ R-EPOCH—rituximab plus EPOCH
Note. Combinations may contain additional chemotherapy drugs in long use for 
many types of cancer. 
Note. Based on information from National Comprehensive Cancer Network, 2016d. 
 ɔ Alemtuzumab
 ɔ Belinostat
 ɔ Bendamustine hydrochloride
 ɔ Bleomycin
 ɔ Bortezomib




 ɔ Denileukin diftitox
 ɔ Dexamethasone
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VOLUME 21, NUMBER 1 CLINICAL JOURNAL OF ONCOLOGY NURSING 5CJON.ONS.ORG
 
to patients (Basch et al., 2006, 2009, 2014; Brunner et al., 2011; 
Dueck et al., 2015; Pakhomov et al., 2008; Quinten et al., 2011). In 
other words, the CTCAE may fail to provide the evidence needed 
for patient–clinician agreement on AEs, a key measure of grading 
validity (Pakhomov et al., 2008). In addition, CTCAE criteria, al-
though in widespread use for decades, have never been formally 
validated (Trotti et al., 2007), further compromising CTCAE evi-
dence on the severity of AEs. Because evidence is the input for the 
critical thinking process, attaining the output of accurate grading 
can be difficult with the current CTCAE. 
Another aspect that impedes critical thinking in grading 
AEs resides in the language of the CTCAE. Grading verbiage 
has changed between CTCAE version 3.0 (NCI, 2006) and the 
current version 4.03 (NCI, 2010). Different clinicians may use 
different terminology depending on the version with which 
they were trained, leading to inconsistent critical analyses. This 
problem has been documented for hypersensitivity infusion re-
actions (DeMoor et al., 2011). A review of 222 cases of hypersen-
sitivity infusion reactions found that different versions of the 
grading system led to inconsistencies in grading and clinician 
response to the reaction in about 50% of cases (DeMoor et al., 
2011).
The significant weaknesses in the CTCAE has prompted ac-
tion by the NCI. To overcome the incompleteness and lack of 
validation, the NCI has spearheaded the development of the 
Patient-Reported Outcomes CTCAE (PRO-CTCAE) for use in 
clinical trials (Basch et al., 2014; Brunner et al., 2011). Although 
the PRO-CTCAE has not been adapted for use in community 
clinical practice, its validation study did include patients with 
lymphoma (Basch et al., 2014), and its implementation in the re-
search setting is instructive for all oncology practitioners.
An additional problem in AE grading is the disjunction be-
tween nursing workflow and the critical reasoning process needed 
for grading. The nursing day offers little time for this process. An 
observational study revealed that frequent task switching and un-
predictable demands characterize the nursing workflow (Cornell 
et al., 2010; Cornell, Riordan, Townsend-Gervis, & Mobley, 2011). 
For example, in an observational study, 68% of nurse tasks on 
a pediatric oncology unit were one minute or less in duration 
(Cornell et al., 2011). As a result, nurses rarely encounter the 
conditions—such as workflow control and uninterrupted time—
needed for critical thinking (Cornell et al., 2010, 2011). 
Another issue of concern is nurse visibility and involvement in 
the care of patients with lymphoma. The less present and visible 
nurses are, the less they are able to gather reports, histories, and 
other evidence regarding patients’ AEs. Sustaining a nursing pres-
ence requires greater effort than ever because more oral cancer 
therapies taken by the patient at home have been introduced for the 
treatment of lymphomas (Yagasaki & Komatsu, 2013). Telephonic 
assessment is useful for triage of patients and identification of se-
vere AEs but requires experienced clinicians to conduct interviews 
and supplementation with face-to-face assessments during sched-
uled office visits (Kondo et al., 2015; Towle, 2009).
TABLE 1. 
ACCURACY OF GRADING OF LYMPHOMA THERAPY 





ADVERSE EVENT CASES n N % n N %
Peripheral neuropathy in 
a 65-year-old receiving 
R-CHOP for DLBCL
30 130 23 49 176 28
Neutropenia in a 25-year-old 
receiving ABVD for HL 46 110 42 37 137 27
Neutropenia in a 40-year-old 
receiving BR for FL 47 107 44 66 138 48
Infusion reaction in a 
70-year-old receiving weekly 
rituximab for FL
59 115 51 107 160 67
Infusion reaction in an 
83-year-old receiving weekly 
rituximab for FL
65 114 57 98 156 63
ABVD—doxorubicin, bleomycin, vinblastine, dacarbazine; BR—bendamustine, rituximab; 
DLBCL—diffuse large B-cell lymphoma; FL—follicular lymphoma; HL—Hodgkin lymphoma; 
R-CHOP—rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone 
Note. Participating nurses completed pre- and post-testing for educational evaluation. 
Note. Based on information from Rogers, 2015.
TABLE 2.
COMMON TERMINOLOGY CRITERIA FOR ADVERSE 
EVENTS
GRADE DESCRIPTION
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
2
Moderate; minimal, local, or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living 
(ADLs)a
3
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; 
disabling; limiting self-care ADLsb
4 Life-threatening consequences; urgent intervention indicated
5 Death related to adverse event
a Instrumental ADLs refer to preparing meals, shopping for groceries or clothes, using 
the telephone, or managing money. 
b Self-care ADLs refer to bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not being bedridden. 
Note. From Common Terminology Criteria for Adverse Events [v.4.03], by National 
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Lastly, the specific nature of critical thinking itself within the 
discipline of nursing can pose problems. Experts in critical think-
ing in nursing suggest that, for the nurse, critical thinking occurs 
within social relationships that involve the patient, caregiver, and 
multidisciplinary care team. To think critically in any context, 
including the grading of an AE, presupposes insightful, collegial 
dialogue and shared observation; the nurse cannot make a criti-
cal analysis in isolation (Brenner et al., 2008; Raymond-Seniuk & 
Profetto-McGrath, 2011). This raises a question: In a day full of 
interruptions and task switching, how can nurses find the time to 
exchange ideas with others?
Decision Making
Shared decision making is currently a key model in oncology prac-
tice (Clark, Nelson, Valerio, Gong, Taylor-Fishwick, & Fletcher, 
2009; Frerichs, Hahlweg, Müller, Adis, & Scholl, 2016). Across 
the interprofessional team and between clinicians and patients, 
shared decision making is an empowering partnership in care 
(Clark et al., 2009). When a clinician shares decision making with 
a patient, three supportive roles appear to be most important: 
help the patient understand the issue being decided, listen to the 
patient’s concerns, and include in discussions what matters most 
to the issue (Elwyn et al., 2012; Katz, Belkora, & Elwyn, 2014). 
Shared decision making may be impeded by limitations to critical 
thought. For example, some patients are reluctant to share decision 
making because they engage in “counterfactual thinking,” meaning 
that they may anticipate feeling regret or self-recrimination if they 
share in a decision, like stopping a particular drug related to AEs 
and then, months or years later, experience disease progression 
(Katz et al., 2014). When nurses have difficulty recognizing and 
analyzing such reasoning, they may be unable to fully empower 
the patient as a decision maker.
Within the context of shared decision making, the nurse may 
be called on to offer evidence, in the form of AE grading and nar-
rative description, with critical consideration of quality of life and 
distress related to the AE. With this information, the nurse helps 
the patient participate in the decision to hold treatment or reduce 
the dose. With systemic therapies, the development of a toxici-
ty and establishing its grade typically determines the decision to 
continue, reduce, or hold treatment. For example, the decision to 
reduce bortezomib dose from 1.3 mg/m2 to 1 mg/m2 in mantle-cell 
lymphoma requires precision in grading. If a patient has grade 1 
neuropathy with no impact on quality of life and no pain, then no 
bortezomib dose adjustment is required. However, grade 2 neurop-
athy with pain (with limitations on instrumental activities of daily 
living) and grade 3 neuropathy (limitations on self-care activities of 
daily living) require holding bortezomib until the neurologic toxic-
ity resolves (Millennium Pharmaceuticals, Inc., 2015; NCI, 2010). 
Misgrading could produce dosing or treatment error.
Medication errors are not uncommon, including giving the 
wrong dose and giving a dose after a discontinuation order (Ford, 
Killebrew, Fugitt, Jacobsen, & Prystas, 2006). Nurses attribute er-
rors to factors that unfavorably influence critical thinking (Cornell 
et al., 2010, 2011), such as adding tasks to the workload, chaos in the 
work environment, being swamped or overwhelmed, emotional re-
sponses, and a loss of focus (Roth, Wieck, Fountain, & Haas, 2015; 
Valiee, Peyrovi, & Nasrabadi, 2014). Of note, nurses themselves 
have cited a lack of critical thinking as one of the top five most 
likely causes of nursing errors in the hospital (Roth et al., 2015).
COMMENTARY ON GRADING ADVERSE EVENTS (AEs)
Deborah Watkins Bruner, RN, PhD, FAAN (Advisor)
We have to realize that the [Common Terminology Criteria for Adverse 
Events (CTCAE)] has never been validated. So, we actually don’t expect that 
if two clinicians graded an AE, there would be inter-grader reliability.
It is also important for nurses to know everything that is—and isn’t—in 
the CTCAE. There is no entry for neutropenia in the CTCAE, only entries 
for febrile neutropenia and neutrophil count decreased. But prescribing 
information for antilymphoma therapies may require adjusting dose for 
grades of neutropenia. Nurses have to recognize this disjunction.
Nina Wagner-Johnston, MD (Author)
In many lymphoma subtypes, our goal from the outset is cure. That means 
we want high dose intensity. We don’t want to be reducing or holding 
the dose for toxicity if it isn’t necessary. That’s why getting an accurate 
grade and description of an AE is so important. It’s also why we need good 
communication of the grade and description of the AE, to ensure that any 
dose modifications are based on vetted, analyzed evidence.
Amy Goodrich, MSN, CRNP (Author)
CTCAE grading has flaws, but it still enhances communication between 
clinicians by giving us a similar language. But you don’t just call a physi-
cian and say “grade 2 toxicity” and then drop it. You have to explain that 
toxicity, its features, and why it is important to manage it in this patient.
“Nurses have cited 
a lack of critical 
thinking as one  
of the top five most 
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Communication
Even when AEs are graded accurately, communication of the 
grade and recommended approaches can pose challenges. 
Barriers to effective communication may result from deficits in 
critical thinking relevant to managing AEs in lymphoma. These 
deficits include the following: 
 ɐ Lack of reasoning across relationships—an inability to un-
derstand, anticipate, and compensate for the types of errors 
that may occur between patient report, upload to the med-
ical record, interpretation and CTCAE grading, and sub-
sequent team discussion. These errors can include gaps in 
communication; loss of shared interpretation of symptoms among 
professionals, patients, and caregivers (link loss); and recording 
and documentation errors (Basch et al., 2005) (see Figure 3).
 ɐ Problems in evidence processing—keeping up with new toxicities 
when a novel therapy or regimen is introduced in the already com-
plex care of lymphoma (e.g., diarrhea and cough with idelalisib in 
follicular lymphoma) is challenging (Coutré et al., 2015).
 ɐ Using a terse or incomplete narrative to describe an AE, which 
does not take into account the listener’s need for evidence—
for example, communicating grade only by the number, rath-
er than also describing its clinical features. An example of this 
would be writing or saying only “grade 3 fatigue” with lenalid-
omide without providing information on the patient’s inability 
to find relief with rest, specific limitations in daily activities, 
and how well the patient is coping (Celgene Corporation, 2015; 
NCI, 2010); incomplete narrative also means that a nurse may 
not have documented the details needed to trigger accurate 
grading.
 ɐ Lack of curiosity and self-reflection limits the ability to ask 
questions, solicit feedback, and identify misunderstandings.
Improving Practice: Tools for Thinking Critically 
and Acting Decisively
The nursing community has been an important contributor in 
education to improve critical thinking (Delibovi, 2015). Oncology 
nurses can use the guidance of nurse educators to enhance criti-
cal thinking to improve accuracy in the grading of AEs, to increase 
precision and confidence in recommendations for the adjustment 
of therapy, and to communicate recommended approaches clearly 
and convincingly to aid in the process of shared decision making. 
Cultivating Critical Thinking Skills
The nursing literature has identified several important skills 
for critical thinking among nurses (Brenner et al., 2008; 
Papathanasiou, Kleisaris, Fradelos, Kakou, & Kourkouta, 2014: 
Papp et al., 2014; Phelps et al., 2009; Raymond-Seniuk & Profetto-
McGrath, 2011):
 ɐ Flexibility—the ability to remain curious, to ask questions, to 
stay alert for unexpected circumstances, and to alter precon-
ceived notions on the basis of observations



















Clinician writes in chart
RA reads chart
RA data entry
Patient enters errors directly into database
Clinician-reported outcomes: Traditional paradigm
Patient-reported outcomes: Investigational paradigm
RA—research assistant 
Note. From "Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy," by E. Basch, D. Artz, D. Dulko, K. Scher, P. Sabbatini, M. Hensley, . . . D. Schrag, 2005, Journal of 
Clinical Oncology, 23, p. 3553. Copyright 2005 by American Society of Clinical Oncology. Reprinted with permission.
FIGURE 3.
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 ɐ A systematic and orderly approach to all decision making, in-
cluding a consistent methodology and use of evidence to sup-
port decisions
 ɐ A focus on problem solving
 ɐ The ability to expect, understand, and embrace differences in 
perspective between oneself and other people 
 ɐ Self-reflectiveness and the ability to admit error and uncertainty.
These skills are highly relevant to best practices in the process 
of AE grading, decision making, and communicating in antilym-
phoma therapy (see Figure 4). For example, even a simple best 
practice, such as comparing a blood count or a report of neurop-
athy to the actual text of the CTCAE, cannot be fully actualized 
without critical thinking. The reason is that patient data and best 
practices qualify as what nurse educators term "messy informa-
tion" (Rowles, Morgan, Burns, & Merchant, 2013). Patient data 
can be scattered, fragmented, or incomplete. Best practices may 
be gathered from various potentially conflicting sources, such as 
cancer center memos, published guidelines, first-person articles 
by experts, facility medical directors, and even third-party payors. 
Often, no guidance may exist on how to apply a best practice to a 
particular patient scenario. 
What should be done, for instance, if a patient reports trouble 
buttoning his shirt, but is unable to answer most of the symptom- 
focused questions on the cancer center’s peripheral neuropathy 
assessment tool? To solve this problem, a nurse might analyze the 
patient’s report deeply, reach out once more to the patient for ad-
ditional evidence of neuropathy, and try to understand the differ-
ence between the clinical perspective and the patient’s perspec-
tive on his symptoms—three of the critical thinking skills cited 
earlier in this article. Therefore, to follow best practices, critical 
thinking is required to assimilate and use the messy information 
pertinent to each case (Rowles et al., 2013).
Critical Thinking in Relationship
Considering the perspectives of others is a particularly meaning-
ful part of the nursing skill set (Papp et al., 2014; Raymond-Seniuk 
& Profetto-McGrath, 2011). Part of the definition of a challenged 
thinker, a nurse who struggles to think critically, is resistance to 
consideration of others’ perspectives (Papp et al., 2014). The ef-
fort to “think in relationship” has profound and positive effects on 
communication regarding AEs and adjustment of therapy. When 
explaining an AE or recommending a dose adjustment, it matters 
who receives the explanation or recommendation. Depending on 
prior experience, healthcare professionals, patients, and caregiv-
ers may have different levels of familiarity with grading schema. 
Therefore, when communicating with different individuals, the 
nurse cannot assume that writing or saying “grade 3 sensory neu-
ropathy” will be sufficient. To take into account others’ perspec-
tives, a statement of the grade should be accompanied by a nar-
rative description of the AE that include features, such as onset, 
location, and duration; conditions that worsen or alleviate the AE; 
the nature of the symptoms; severity; and interference with quality 
of life. Nurses may even want to create a template or reminder to 
include these features that functions as a verbal or written script 
for communication. Scripting is a technique borrowed from suc-
cessful nursing education for critical thinking (Su & Juestel, 2010), 
and it may be a useful tool in clinical practice as well.
In antilymphoma therapy, a key aspect of the patient–nurse 
relationship, nursing presence, has become more challenging. 
Challenges to nurse visibility stem from the growing number of 
oral, self-administered therapies available (Yagasaki & Komatsu, 
2013), including approved therapies such as lenalidomide (mantle- 
cell lymphoma), vorinostat (cutaneous T-cell lymphoma), ide-
lalisib (follicular lymphoma, small lymphocytic lymphoma), and 
others (Celgene Corporation, 2015; Gilead Sciences, 2014; Merck 
Sharp & Dohme Co., 2015). When patients receive oral anti- 
lymphoma therapy, “thinking in relationship” is an important 
nursing skill that involves understanding the perspective of the 
patient at home. This patient may be hesitant to make a call to 
report an AE, may forget the importance of watching for AEs, or 
FIGURE 4.
SELECTED BEST PRACTICES IN ADVERSE EVENT 
(AE) GRADING, DOSE ADJUSTMENT, AND 
COMMUNICATION
 ɔ Recognize that errors can occur; anticipate that identification and grading 
of AEs can be difficult, particularly in complex lymphoma regimens.
 ɔ Obtain patient self-reports of symptoms at every interaction, using formal 
assessment tools when available; document self-reports carefully (includ-
ing patient’s reports verbatim).
 ɔ Use outreach methods to sustain nursing visibility, particularly in patients 
taking oral antilymphoma therapies at home; methods include telephonic 
follow-up, email, and patient web portals.
 ɔ Routinely review AE sections of prescribing information for all agents that 
the patient receives.
 ɔ Consult Common Terminology Criteria for Adverse Events (CTCAE) reg-
ularly to harmonize documentation with standard grading terminology; 
post in the nurse’s station or wherever documentation takes place.
 ɔ Compare laboratory results and patient reports to the actual entry in the 
CTCAE; do not rely on memory of the CTCAE when grading, particularly 
for numeric criteria, such as neutrophil counts.
 ɔ Write or verbalize for the team a clear, full, narrative description, along 
with CTCAE grade, of every AE that may need intervention.
 ɔ Never give or accept verbal orders for dose adjustments; make written 
orders standard.
 ɔ Double check dose modifications and supportive care decisions with 
pharmacy.
Note. Based on information from Basch et al., 2009; Jacobsen et al., 2009; 












































































































 ɔ Understand that a growing number of treatment options, combined 
with the heterogeneity of Hodgkin and non-Hodgkin lymphomas, 
have created nursing challenges in the management of adverse 
events (AEs).
 ɔ Prepare for challenges regarding accurate grading, shared 
decision making in the adjustment of therapy based on grade, and 
communication of action plans to the interdisciplinary team and 
the patient.
 ɔ Meet these challenges by developing critical thinking skills, thinking 
in relation to recognize the perspectives of others, leveraging in-
formation from patient-reported outcomes for AEs, and managing 
workflow to facilitate critical thinking.
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may generally feel more distant from the nurse. Understanding 
the patient’s perspective in such cases can prompt nurses to 
make more frequent and vigorous outreach by phone or email or 
on the occasion of a visit to the cancer center.
Leverage Learning From the PRO-CTCAE
The patient-centric PRO-CTCAE has been shown to be valid, re-
liable, and responsive, indicating that its patient-centeredness 
is an asset (Dueck et al., 2015). It also is designed to help mini-
mize communication gaps, link loss, and problems in recording 
error (Basch et al., 2005, 2014). PRO-CTCAE use is gaining mo-
mentum in the clinical trial setting, but is not yet widely used 
in clinical care.
Questions posed to patients via the PRO-CTCAE were de-
signed with three features: plain language terminology for the 
symptom; a focus on eliciting frequency, severity, and interference 
with activity from the patient; and a mechanism to gather the re-
call period for the symptom (Basch et al., 2014). Sample question 
formats include: “In the past, how OFTEN did you have [symp-
tom]?”; “In the past, what was the SEVERITY of your [symptom] 
at its worst?”; “In the past, how much did [symptom] INTERFERE 
with your usual or daily activities?” (Basch et al., 2014, p. 1). Data 
have shown a strong consensus among key stakeholders in the im-
plementation of the PRO-CTCAE that including patient reporting 
of adverse symptoms would be useful for improving understand-
ing of the patient experience in a cancer clinical trial (Brunner et 
al., 2011). In addition, a high proportion of stakeholders endorsed 
administration of PRO-CTCAE clinical trials to improve com-
pleteness, accuracy, and efficiency of AE data collection (Brunner 
et al., 2011) (see Figure 5). These findings may suggest that nurses 
in community clinical practice may gather better input for critical 
analysis of CTCAE grade by asking patients to describe their own 
experience of frequency, severity, and interference with an AE, po-
tentially leading to more accurate grading.
Manage Workflow
Chaos and task switching are part of the nursing day, but they 
are not conducive to the critical thinking needed for accurate 
grading, confident decision making on the adjustment of therapy, 
and well-organized communication (Cornell et al., 2010, 2011). 
Interventions to improve workflow may have a positive impact on 
critical thinking (Cornell et al., 2011). These include methods that 
nurses can deploy themselves, such as seeking out education on 
time and workflow management, delegation of routine or repet-
itive tasks to non-nursing staff, and more skillful and systematic 
use of technology (Cornell et al., 2011). Other methods must be 
championed at the institutional level, such as workflow evalua-
tion and redesign, implementation of better software systems, 
and reallocation of duties (Cornell et al., 2011).
Conclusion
In antilymphoma therapy, proper management of AEs is es-
sential to good clinical outcomes. The response to AEs cannot 
be optimal without precise grading of toxicities, adjustment of 
therapy based on grade and AE description, and effective in-
terdisciplinary and patient–clinician communication. Building 
FIGURE 5.
PRO-CTCAE STAKEHOLDERS RATING  
OF PATIENT-REPORTED OUTCOMES IN 
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PR1—useful to improve understanding of patient experience; PR2—improved 
completeness of symptom data collection; PR3—improved accuracy of symp-
tom data collection; PR4—improved efficiency of symptom data collection; 
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nursing competency in these areas requires development of 
critical thinking, which enables nurses to implement best prac-
tices decisively and appropriately in each clinical case.
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APPENDIX A.
CASE STUDY: CRITICAL THINKING SKILLS AND METHODS FOR ORAL MUCOSITIS
SETTING
K.L. is an oncology nurse in a suburban group practice with an infusion center. 
The patient, M.G., is a 60-year-old man newly diagnosed with follicular lympho-
ma who is receiving six planned cycles of bendamustine and rituximab (BR). 
PERSPECTIVE TAKING, LEVERAGING THE PRO-CTCAE
M.G. said that he hates to bother people with his problems. Because K.L. consid-
ers M.G.’s perspective, she always asks him specific questions about symptoms 
while reassuring him that his problems are important to the team. During a 
call three days before the last of M.G.’s six BR cycles, K.L.’s question, "Are you 
feeling anything that interferes with your daily life?" prompts M.G. to say that his 
mouth is so sore that he does not want to eat and cannot eat anything crunchy. 
More discussion reveals a symptom pattern commensurate with oral mucositis 
(stomatitis). K.L. asks M.G. to come in for an examination, and she and the 
physician document visible redness and a small sore on the tongue. K.L. asks 
the physician and another nurse on the team to confirm orders for self-care (ice 
chips, soft food) and topical treatment.
SYSTEMATIC APPROACH TO SHARED DECISION MAKING AND 
WORKFLOW MANAGEMENT
In preparation for a team meeting, K.L. uses her 20 minutes of daily planning 
time, which she specifically requested from her employers, to chart the infor-
mation on M.G.’s reported symptoms. She compares her learnings to the CTCAE 
and determines that she needs more information: (a) the nature of mouth 
irritation with rituximab versus bendamustine and (b) how much mouth pain, on 
a scale of 1–10, M.G. is experiencing. K.L. checks the prescribing information for 
the two drugs and telephones M.G. to obtain his numeric pain rating. 
PERSPECTIVE TAKING, FOCUS ON PROBLEM SOLVING, WILLINGNESS 
TO ANALYZE DEEPLY
Several others at the meeting, including M.G.’s physician and the practice man-
ager, need more information than just the CTCAE grade. For this reason, K.L. has 
notes for a narrative description:
 ɔ Based on phone interviews, M.G. has grade 3 oral mucositis, graded in this 
way because of interference with oral food intake and pain of moderate to 
severe intensity, measured as 6 on a 10-point pain scale.
 ɔ Symptoms have been present and increasing gradually for four weeks.
 ɔ The most likely cause is bendamustine chemotherapy, but rituximab can 
cause mucocutaneous reactions as well. 
The physician notes that the prescribing information for bendamustine 
regarding stomatitis does not specify when to hold or decrease the dose for 
this AE. Another nurse on the team, as well as the practice manager, share this 
experience: In another case of grade 3 oral mucositis where the patient was 
very far along in bendamustine treatment, the team gave the final cycle of the 
chemotherapy with no dose reduction while continuing to provide self-care 
methods and topical treatment to control the pain and irritation.
The team decides to recommend this approach, and K.L. discusses it with M.G. 
when he arrives for his treatment. K.L., in concert with the physician, presents 
the team’s reasoning process and supporting evidence. M.G. expresses a wish 
not to hold the last dose chemotherapy; he wants to complete his cycles and 
notes that self-care in the past few days has already helped. M.G. shares in the 
decision to go ahead with the last cycle of BR.
FLEXIBILITY AND ABILITY TO ADMIT UNCERTAINTY
After the treatment, M.G.’s physician contacts K.L. and the practice manager 
to offer a caveat: Because rituximab has not been completely ruled out as a 
cause, M.G.’s symptom pattern should be followed telephonically for a number 
of weeks after this last BR treatment. This is recommended because muco-
cutaneous reactions to rituximab can signal serious adverse events, such as 
Stevens-Johnson syndrome, and require discontinuation. K.L. agrees to provide 
this follow up.
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